Updated:
MH Innov
Malakoff Humanis Investissements Privés was established in 2020 as the dedicated investment arm of the Malakoff Médéric insurance group. Thomas Saunier serves...
MH Innov
Malakoff Humanis Investissements Privés was established in 2020 as the dedicated investment arm of the Malakoff Médéric insurance group. Thomas Saunier serves as group CEO. The structure channels premiums and reserves from health, retirement, and employee savings products into a mix of venture, private credit, and real estate exposures. MH Innov allocates across early-stage venture, growth equity, and select buyout opportunities. Confirmed holdings include SURGAR, i-Virtual, Primaa, Sêmeia, Surge, Klaro, and Mon Petit Placement, all French healthcare technology or fintech startups. It also holds full ownership of Magnolia.fr and majority stakes in Epsens and UNOFI. Geographic focus remains France with limited European co-investments through partnerships such as Elaia Partners. The firm participates in both fund commitments and direct LP positions. The group reports approximately €20 billion in assets under management within its investment activities. It maintains a headquarters campus at 21 Rue Laffitte in Paris and additional real estate holdings through Malakoff Humanis Puccini. In October 2024 MH Innov attended the 0100 Conference Mediterranean in Milan for LP/GP networking. Adjacent vehicles include the Fondation Malakoff Humanis Handicap, which directs philanthropic capital toward disability inclusion programs in France. MH Innov operates as an insurance-owned allocator rather than a standalone family office or independent asset manager. Its mandate requires integration with the group's Article 8 SFDR funds and ongoing ESG scoring applied to every commitment. This creates a direct link between insurance liabilities and long-duration private market deployment.
General information
Firm type
Insurance
Year founded
2020
AUM
Undisclosed
Location
Region
Europe
Country
France
City
Paris
Corporate office
21 Rue Laffitte, 75009 Paris, France
Sector focus
Frequently asked questions
Who runs investment decisions at MH Innov?
Thomas Saunier serves as group CEO. Investment execution is led by Aurélie Baudhuin as Investment Director and Gauthier Lalande through the France Invest Impact Commission.
Does MH Innov participate in fund commitments or only direct deals?
MH Innov runs both fund commitments and direct LP positions. It maintains a dedicated early-stage vehicle with Elaia Partners and holds direct stakes in multiple French startups.
What investment stages does MH Innov typically target?
The firm focuses on early-stage seed and startup rounds in healthcare technology and fintech. It also maintains exposure to growth, mezzanine, and select buyout opportunities.
Where does the underlying wealth come from?
Capital originates from the Malakoff Humanis insurance and mutual group, which manages health coverage, supplementary pensions, and employee savings products.
How is MH Innov related to Sienna Investment Managers?
MH Innov maintains a strategic partnership with Sienna for retirement and employee savings products and is acquiring Sienna's asset management and private debt activities.
Does MH Innov maintain philanthropic structures?
Yes. The Fondation Malakoff Humanis Handicap directs capital toward disability inclusion and has supported accessibility projects at Palais de Tokyo, La Villette, and Opéra-Comique.
What is MH Innov's known posture on co-investments alongside external GPs?
MH Innov co-invests through joint real estate vehicles with Amundi Immobilier, Covéa, and Crédit Agricole Assurances and maintains venture partnerships such as the one with Elaia Partners.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: